All In Biotech

Drug Trial Radar · NCT00014222

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

A Phase III Adjuvant Trial Of Sequenced EC + Filgrastim + Epoetin Alfa Followed By Paclitaxel Versus Sequenced AC Followed By Paclitaxel Versus CEF As Therapy For Premenopausal Women And Early Postmenopausal Women Who Have Had Potentially Curative Surgery For Node Positive Or High Risk Node Negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,104

Actual

Start

Dec 4, 2000

Primary completion

Feb 10, 2014

Study completion Mar 17, 2014

Sponsor

Lead sponsor
NCIC Clinical Trials GroupResearch network
Sponsor type
Research network
Collaborators
North Central Cancer Treatment Group; SWOG Cancer Research Network; Cancer and Leukemia Group B
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy given with or without epoetin alfa in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.

Conditions

  • Breast Cancer

Interventions

  • epoetin alfaBiological

    40,000 IU

  • filgrastimBiological

    5 mg/kg/d - days 2-13

  • cyclophosphamideDrug

    75, 600 and 830 mg/m2

  • doxorubicin hydrochlorideDrug

    60 mg/m2

  • epirubicin hydrochlorideDrug

    60 mg/m2

  • fluorouracilDrug

    500mg/m2

  • paclitaxelDrug

    175 mg/m2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Free SurvivalTime frame: 13 years

Locations

78 sites in 2 countries. Site status is shown where the registry gives one.

  • Sparks-Arkansas Oklahoma Cancer Treatment Centre

    Fort Smith, Arkansas

  • Hematology Oncology Services of Arkansas

    Little Rock, Arkansas

  • Scripps Cancer Center

    La Jolla, California

  • University of Colorado Cancer Centre

    Aurora, Colorado

  • Greenwich Hospital - Bendheim Cancer Center

    Greenwich, Connecticut

  • Sibley Memorial Hospital, Oncology Research

    Washington D.C., District of Columbia

  • Comprehensive Cancer Care Centre at Boca Raton

    Boca Raton, Florida

  • University of Florida

    Gainesville, Florida

  • Florida Oncology Associates

    Orange Park, Florida

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Therapy Associates, Inc., Hematology/Oncology

    Evansville, Indiana

  • Lexington Oncology Assts./Central Baptist Hospital

    Lexington, Kentucky

  • Consultants in Blood Disorders and Cancer

    Louisville, Kentucky

  • CHRISTUS Schumpert Medical Center - Hem/Onc Clinic

    Shreveport, Louisiana

  • Willis-Knighton Cancer Center

    Shreveport, Louisiana

  • Maine Center for Cancer Medicine and Blood Disorders

    Scarborough, Maine

  • Maine General Medical Center

    Waterville, Maine

  • Suburban Hospital Cancer Program

    Bethesda, Maryland

  • Associates in Oncology/Hematology

    Rockville, Maryland

  • Saint Joseph Medical Center, Cancer Care Program

    Towson, Maryland

  • Baystate Regional Cancer Program

    Springfield, Massachusetts

  • St. Luke's Cancer Care Centre

    Duluth, Minnesota

  • University of Minnesota Cancer Centre

    Minneapolis, Minnesota

  • Columbia-Capitol Comprehensive Care Clinics

    Jefferson City, Missouri

  • Saint Louis University Hospital

    St Louis, Missouri

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • Creighton University Cancer Centre

    Omaha, Nebraska

  • Advanced Oncology Associates

    Armonk, New York

  • Queens Medical Associates, PC

    Fresh Meadows, New York

  • Winthrop University Hospital Onc/Hem

    Mineola, New York

  • Hematology Oncol. Associates Rockland

    Nyack, New York

  • University of Rochester

    Rochester, New York

  • Staten Island University Hospital

    Staten Island, New York

  • Our Lady of Mercy Medical Center

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • ECU School of Medicine, Leo Jenkins Cancer Center

    Greenville, North Carolina

  • Oncology/Hematology Care, Inc.

    Cincinnati, Ohio

  • Pottstown Memorial Regional Cancer Centre

    Pottstown, Pennsylvania

  • Santee Hematology Oncology

    Sumter, South Carolina

  • University Oncology and Hematology Associates

    Chattanooga, Tennessee

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.